2021
Willingness to Get the COVID-19 Vaccine among Residents of Slum Settlements
Ticona J, Nery N, Victoriano R, Fofana MO, Ribeiro GS, Giorgi E, Reis MG, Ko AI, Costa F. Willingness to Get the COVID-19 Vaccine among Residents of Slum Settlements. Vaccines 2021, 9: 951. PMID: 34579188, PMCID: PMC8472908, DOI: 10.3390/vaccines9090951.Peer-Reviewed Original ResearchVaccine hesitancyCOVID-19 vaccine acceptanceCOVID-19 vaccine hesitancyImportance of vaccinationCOVID-19 infectionCOVID-19 vaccinePotential side effectsCOVID-19Vaccine efficacyCOVID-19 casesVaccine acceptanceVaccine intentionsGeneral populationHigh incidenceSpecific treatmentSide effectsHealth historySalvador-BrazilMultivariate analysisYounger ageVaccineSlum residentsSlum settingsVaccinationSlum communitiesThe escalating tuberculosis crisis in central and South American prisons
Walter KS, Martinez L, Arakaki-Sanchez D, Sequera VG, Sanabria G, Cohen T, Ko AI, García-Basteiro AL, Rueda ZV, López-Olarte RA, Espinal MA, Croda J, Andrews JR. The escalating tuberculosis crisis in central and South American prisons. The Lancet 2021, 397: 1591-1596. PMID: 33838724, PMCID: PMC9393884, DOI: 10.1016/s0140-6736(20)32578-2.Peer-Reviewed Original ResearchIncidence and prevalence of tuberculosis in incarcerated populations: a systematic review and meta-analysis
Cords O, Martinez L, Warren JL, O’Marr J, Walter KS, Cohen T, Zheng J, Ko AI, Croda J, Andrews JR. Incidence and prevalence of tuberculosis in incarcerated populations: a systematic review and meta-analysis. The Lancet Public Health 2021, 6: e300-e308. PMID: 33765455, PMCID: PMC8168455, DOI: 10.1016/s2468-2667(21)00025-6.Peer-Reviewed Original ResearchConceptsPrevalence of tuberculosisIncidence of tuberculosisM tuberculosis infectionIncidence rate ratiosTuberculosis infectionGeneral populationSystematic reviewSouth-East Asia RegionIncarcerated populationsPopulation-level incidenceMycobacterium tuberculosis infectionRate ratioTuberculosis Control ProgrammeLILACS electronic databasesWHO Eastern Mediterranean RegionWHO South-East Asia RegionWeb of KnowledgeCohort studyUS National InstitutesSubgroup analysisPooled estimatesHigh riskElectronic databasesPreventive interventionsTuberculosis
2020
Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study
Mahajan S, Srinivasan R, Redlich CA, Huston SK, Anastasio KM, Cashman L, Massey DS, Dugan A, Witters D, Marlar J, Li SX, Lin Z, Hodge D, Chattopadhyay M, Adams MD, Lee C, Rao LV, Stewart C, Kuppusamy K, Ko AI, Krumholz HM. Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study. The American Journal Of Medicine 2020, 134: 526-534.e11. PMID: 33130124, PMCID: PMC7598362, DOI: 10.1016/j.amjmed.2020.09.024.Peer-Reviewed Original ResearchConceptsSARS-CoV-2-specific IgG antibodiesWeighted seroprevalenceIgG antibodiesSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodiesSARS-CoV-2-specific antibodiesConnecticut residentsSelf-reported adherenceImmunoglobulin G antibodiesSARS-CoV-2Symptomatic illnessSerology testingSeroprevalence studyG antibodiesPrevalence studyGeneral populationPercentage of peopleSeroprevalenceLack antibodiesMajority of respondentsAntibodiesHispanic subpopulationsConvenience sampleHispanic populationCOVID-19Risk mitigation behaviors